| avenciguat (BI 685509) / Boehringer Ingelheim |
NCT04736628 / 2020-002930-33: A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease |
|
|
| Completed | 2 | 261 | Europe, Canada, Japan, US, RoW | Avenciguat, BI 685509, Placebo | Boehringer Ingelheim | Chronic Kidney Disease | 08/23 | 09/23 | | |
NCT05282121 / 2021-005171-40: A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) |
|
|
| Terminated | 2 | 90 | Europe, Canada, Japan, US, RoW | Avenciguat (BI 685509), Empagliflozin | Boehringer Ingelheim | Liver Diseases, Hypertension, Portal | 04/24 | 06/24 | | |
NCT06082843: A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly |
|
|
| Terminated | 2 | 22 | Europe, Canada, Japan, US, RoW | Placebo, Avenciguat (BI 685509) | Boehringer Ingelheim | Hypertension, Portal, Liver Cirrhosis | 05/24 | 05/24 | | |
NCT05161481 / 2021-001285-38: A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live |
|
|
| Terminated | 2 | 80 | Europe, Canada, Japan, US, RoW | Avenciguat (BI 685509), Placebo matching Avenciguat (BI 685509) | Boehringer Ingelheim | Hypertension, Portal | 05/24 | 06/24 | | |
NCT05559580: A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms |
|
|
| Active, not recruiting | 2 | 188 | Europe, Canada, Japan, US, RoW | Avenciguat (BI 685509), Placebo | Boehringer Ingelheim | Scleroderma, Systemic | 10/25 | 11/25 | | |
NCT06193811: A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood |
|
|
| Completed | 1 | 16 | Europe | Avenciguat (BI 685509) (intended commercial formulation (iCF)), Avenciguat (BI 685509) (trial formulation 2 (TF2)), esomeprazole | Boehringer Ingelheim | Healthy | 03/24 | 03/24 | | |
NCT06272058: A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems |
|
|
| Terminated | 1 | 4 | US | Avenciguat (BI 685509) | Boehringer Ingelheim | Healthy, Liver Diseases | 10/24 | 10/24 | | |
